Avoro Capital Advisors Reduces Its Stake in ETNB ($ETNB)
Avoro Capital Advisors liquidated its entire position in ETNB, offloading 6.39 million shares.
Key Points
- Avoro Capital Advisors sold all 6.39 million shares of ETNB, exiting the position entirely as of the latest 13F filing.
- Other funds like IFP Advisors and DekaBank also sold out of ETNB, indicating a broader divestment trend.
- HC Wainwright & Co. downgraded ETNB to a hold with a $14.5 target, while Citigroup initiated a buy with a $25 target.
Avoro Capital Advisors has completely exited its position in ETNB, selling all 6,387,790 shares. This move was disclosed in a recent 13F filing with the SEC, which reflects holdings as of the reporting period and may not represent the fund's current position.
What Changed in Avoro Capital Advisors' ETNB Position
Avoro Capital Advisors cut its entire stake in ETNB, selling off 6,387,790 shares. Previously, the fund held the same number of shares, indicating a full divestment from the company.
Other Institutional Activity in ETNB
Other institutional investors also reduced their positions in ETNB. IFP Advisors, Inc. sold 17 shares, leaving it with no remaining holdings. Similarly, DekaBank Deutsche Girozentrale liquidated its position by selling 90,000 shares, also ending with zero shares.
Insider Buying and Selling at ETNB
RA Capital Management, L.P. was active in selling ETNB shares on October 30, 2025. The firm sold 19,889,683 shares in one transaction and 4,331,081 shares in another, among other smaller sales. These transactions were not part of a pre-planned 10b5-1 trading plan.
Analysts Set New Price Targets
Analyst activity around ETNB has been mixed. On September 19, 2025, HC Wainwright & Co. downgraded ETNB to a hold with a price target of $14.5. Earlier, on September 4, 2025, the same firm assumed coverage with a buy rating and a $32 target. B of A Securities maintained a buy rating on August 25, 2025, with a $29 target, while RBC Capital maintained a hold with an $11 target on August 8, 2025.
About ETNB
ETNB operates within the biotechnology sector, focusing on developing novel therapies for various medical conditions. The company is engaged in research and development to address unmet medical needs, although specific details about its headquarters, CEO, and employee count were not provided.
Bottom Line
Avoro Capital Advisors' decision to sell its entire stake in ETNB might reflect a strategic shift or a response to market conditions. Other institutional investors also divested, suggesting a broader trend. While analyst opinions vary, with some maintaining a buy stance, the overall sentiment shows caution. As always, 13F filings are backward-looking and may not indicate current positions.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.